TCGA-50-5942-01A-21R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.350
- UV_RESPONSE_DN+0.350
- BILE_ACID_METABOLISM+0.280
- HEDGEHOG_SIGNALING+0.240
- NOTCH_SIGNALING+0.200
- KRAS_SIGNALING_DN+0.190
- ANDROGEN_RESPONSE+0.170
- PANCREAS_BETA_CELLS+0.160
- COAGULATION+0.140
- KRAS_SIGNALING_UP+0.120
Top 10 suppressed
- E2F_TARGETS-0.620
- MYC_TARGETS_V2-0.590
- G2M_CHECKPOINT-0.570
- MTORC1_SIGNALING-0.530
- MYC_TARGETS_V1-0.500
- OXIDATIVE_PHOSPHORYLATION-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- UNFOLDED_PROTEIN_RESPONSE-0.400
- PI3K_AKT_MTOR_SIGNALING-0.390
- GLYCOLYSIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.942 |
| 2 | SRR8613705 | — | A | 0.921 |
| 3 | C3L-03268 | — | cohortA1 | 0.914 |
| 4 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.898 |
| 5 | TCGA-86-7714-01A-12R-2170-07 | — | cohortA1 | 0.890 |
| 6 | 5c61f3fb-d3c5-4628-89a8-94bd513e8fa4 | — | — | 0.887 |
| 7 | SRR6013492 | — | cohortA1 | 0.878 |
| 8 | C3N-03911 | — | cohortA1 | 0.876 |
| 9 | 65f86d9a-828b-4e8b-a656-38baba5a54f7 | — | — | 0.874 |
| 10 | SRR8518381 | — | A | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |